Merrimack Pharmaceuticals, Inc.
(NASDAQ : MACK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
2.36%204.021.3%$749.47m
GILDGilead Sciences, Inc.
0.43%63.140.9%$384.23m
CELGCelgene Corporation
1.53%94.741.3%$360.74m
ILMNIllumina, Inc.
0.49%286.173.5%$321.19m
BIIBBiogen Inc.
1.78%231.681.3%$305.34m
VRTXVertex Pharmaceuticals Incorporated
2.11%184.941.9%$260.38m
EXASExact Sciences Corporation
1.35%119.8224.1%$245.81m
ALXNAlexion Pharmaceuticals, Inc.
1.66%110.852.0%$238.74m
REGNRegeneron Pharmaceuticals, Inc.
1.28%296.852.6%$212.35m
AAgilent Technologies, Inc.
2.18%71.111.6%$206.33m
SRPTSarepta Therapeutics, Inc.
2.44%124.9514.7%$156.17m
INCYIncyte Corporation
3.11%83.122.5%$97.22m
BMRNBioMarin Pharmaceutical Inc.
6.65%76.504.3%$91.98m
SGENSeattle Genetics, Inc.
3.25%79.206.5%$90.21m

Company Profile

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.